跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Aviptadil
首页
药物
Aviptadil
Experimental
Small Molecule
Aviptadil
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
技术标识符
化学式
C
145
H
232
N
40
O
43
S
CAS 编号
40077-57-4
UNII ID
A67JUW790C
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Method of treating men with testosterone supplement and 5alpha reductase inhibitor
EP 2371367 A1
申请人: MERCK SHARP & DOHME
优先权: 2006
EP
US
2 件公开
Dosage regimen for inhaled vasoactive intestinal polypeptide
US 11918627 B2
申请人: CENTURION ÌLAC SANAYI VE TICARET ANONIM SIRKETI
优先权: 2020
CN
US
2 件公开
Formulation for aviptadil
US 8178489 B2
申请人: BACHER GERALD
优先权: 2006
US
2 件公开
METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION
US 2011092470 A1
申请人: MEEHAN ALAN
优先权: 2010
US
2 件公开
ADMINISTRATION OF AVIPTADIL BY INHALATION TO TREAT CHRONIC BERYLLIUM DISEASE
EP 3583933 A1
申请人: UNIV FREIBURG ALBERT LUDWIGS
优先权: 2018
EP
Use of vasoactive intestinal peptide (VIP) for treatment of drug-induced pneumonia
CN 114144195 A
申请人: ADEVEITA LIFE SCIENCE LTD RESPONSIBILITY COMPANY
优先权: 2019
CN
USE OF AVIPTADIL ALONE OR IN COMBINATION WITH ALPHA LIPOIC ACID AS A THERAPEUTIC MEDICAMENT FOR POST-VIRAL INFECTION SYNDROME
US 2024181014 A1
申请人: ADVITA LIFESCIENCE AG
优先权: 2021
US
Stable aviptadil formulations
CN 120152699 A
申请人: RELIVE PHARMA INT INC
优先权: 2022
CN
A COMBINATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR AGONIST AND A MUCOLYTIC AGENT AGAINST INFLAMMATORY DISEASES OF THE RESPIRATORY TRACT
WO 2025210089 A1
申请人: REVISAN HEALTHCARE GMBH
优先权: 2024
WO
Polypeptide methionine site thioimine modification method and application thereof
CN 118978566 A
申请人: UNIV LANZHOU
优先权: 2024
CN
第 1 / 2 页
上一页
下一页
药物
反馈